Tumor-selective immunotherapy for cancer
Xilio Therapeutics (xiliotx.com) scores 75 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 48th percentile of 21634 Healthcare brands.
Xilio Therapeutics is a clinical-stage biotechnology company headquartered in Waltham, founded in 2015. It develops masked immuno-oncology therapies using proprietary, clinically-validated masking technology designed to activate potent immunotherapies specifically within tumors, aiming to reduce severe systemic side effects associated with conventional immunotherapies. The company targets cancer patients, oncologists, biopharmaceutical partners, and investors interested in next-generation cancer treatments.
| Brand Name | Xilio Therapeutics |
|---|---|
| Domain | xiliotx.com |
| Industry | Healthcare |
| Founded | 2015 |
| Headquarters | Waltham |
| Main Competitors | CytomX Therapeutics (76/100), BioAtla (70/100), Werewolf Therapeutics (71/100), Janux Therapeutics (70/100) |
Moz Domain Authority 34/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #3,380,995 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We are committed to transforming cancer treatment by unleashing the full power of highly potent immunotherapies precisely in the tumors. Learn more about Xilio Therapeutics." (Meta description: 25 words (ideal length). OG description present but brief) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Product/Article schema, og:title, og:description, og:image, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Nginx, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram; no detected presence on YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Xilio Therapeutics?", Claude could identify the brand as of September 2026. Xilio Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immuno-oncology therapies designed to localize immune activation within tumors while sparing healthy tissue, aiming to reduce systemic toxicity seen with existing immunotherapies. Its pipe Best known for Developing tumor-activated (masked) immuno-oncology therapies designed to reduce systemic toxicity of immunotherapy.
When asked "Best brands similar to Xilio Therapeutics?", Claude would recommend Xilio Therapeutics as of September 2026. It's a recognizable name in the tumor-selective immuno-oncology space, relevant if someone is comparing clinical-stage biotechs working on masked antibody or cytokine therapies.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Xilio Therapeutics's main competitors in Healthcare: CytomX Therapeutics (76/100), BioAtla (70/100), Werewolf Therapeutics (71/100), Janux Therapeutics (70/100).
Sources: Brand Analyzer scan
Xilio Therapeutics is a clinical-stage biotechnology company based in Waltham, founded in 2015. It focuses on developing masked immuno-oncology therapies intended to be activated specifically within tumors, with the goal of transforming cancer treatment by improving the safety and effectiveness of highly potent immunotherapies.
Sources: Xilio Therapeutics official site
Xilio Therapeutics has limited AI-search visibility, scoring 30/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 29, recommendation 48). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Xilio Therapeutics official site
Xilio Therapeutics was founded in 2015. Xilio Therapeutics operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Xilio Therapeutics is headquartered in Waltham. Xilio Therapeutics operates in the Healthcare category.
Sources: Wikidata
Xilio Therapeutics develops masked immunotherapies for cancer treatment. Using clinically-validated masking technology, the company designs treatments that remain inactive until they reach the tumor microenvironment, where they are activated to deliver potent immuno-oncology effects while minimizing systemic toxicity elsewhere in the body.
Sources: Xilio Therapeutics official site
Xilio Therapeutics scores 48/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Xilio Therapeutics official site
Xilio Therapeutics can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Xilio Therapeutics official site
Xilio Therapeutics is known for its tumor-selective 'masking' technology platform, which is designed to activate highly potent immunotherapies specifically within tumors rather than throughout the body, addressing a key limitation of conventional immuno-oncology treatments-severe systemic side effects.
Sources: Xilio Therapeutics official site
Xilio Therapeutics' work is relevant to cancer patients who may eventually benefit from its therapies, oncologists who treat cancer patients, biopharmaceutical partners collaborating on drug development, and investors interested in next-generation immuno-oncology treatments.
Sources: Xilio Therapeutics official site
Xilio Therapeutics scores 30/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Xilio Therapeutics has a weak AI-visibility profile at 30/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (48/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #3,380,995 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 34/100 and thin schema.org structured data. In a live check, Claude could already identify Xilio Therapeutics from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Xilio Therapeutics: Xencor (75/100), Xcel Delivery Service (75/100), XLNTBrain (75/100), X/procure (75/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.